High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy

Antonio Heras-Garvin 1, Violetta Refolo 1, Markus Reindl 2, Gregor K. Wenning 1 and Nadia Stefanova 1*

Abstract

Aim: Pre-clinical studies in models of multiple sclerosis and other inflammatory disorders suggest that high-salt diet may induce activation of the immune system and potentiate inflammation. However, high-salt diet constitutes a common non-pharmacological intervention to treat autonomic problems in synucleinopathies such as Parkinson’s disease and multiple system atrophy. Since neuroinflammation plays an important pathogenic role in these neurodegenerative disorders, we asked here whether high-salt diet may aggravate the disease phenotype in a transgenic model of multiple system atrophy.

Methods: Nine-month-old PLP-hαSyn and matched wildtype mice received normal or high-salt diet for a period of 3 months. Behavioral, histological, and molecular analyses were performed to evaluate the effect of high-salt diet on motor decline, neuroinflammation, neurodegeneration, and α-synuclein accumulation in these mice.

Results: Brain subregion-specific molecular and histological analyses showed no deleterious effects of high-salt diet on the level of microglial activation. Moreover, neuroinflammation-related cytokines and chemokines, T cell recruitment or astrogliosis were unaffected by high-salt diet exposure. Behavioral testing showed no effect of diet on motor decline. High-salt diet was not related to the deterioration of neurodegeneration or α-synuclein accumulation in PLP-hαSyn mice.

Conclusions: Here, we demonstrate that high-salt diet does not aggravate neuroinflammation and neurodegeneration in PLP-hαSyn mice. Our findings discard a deleterious pro-neuroinflammatory effect of high-salt diet in multiple system atrophy.

Keywords: Neuroinflammation, High-salt diet, α-Synuclein, Multiple system atrophy, Parkinson’s disease

Introduction

High-salt diet (HSD) has been associated with chronic inflammation [1], neuroinflammation [2, 3], and autoimmune diseases [4, 5]. In this regard, high-salt intake has been shown to affect immune cells and induce the differentiation of T helper (Th)17 cells with pathogenic phenotype [6, 7] which play an important role in the induction of neuroinflammation, CNS autoimmunity, and neurovascular and cognitive dysfunction [8–11]. The induction of pathogenic Th17 cells and their infiltration in the CNS by HSD has shown to potentiate neuroinflammation in experimental autoimmune encephalomyelitis (EAE), an animal model which mimics many features of multiple sclerosis (MS) [6, 9, 12, 13]. In this mouse model, HSD accelerates disease onset, augments its severity, and enhances blood-brain barrier (BBB) disruption and brain pathology [6, 7, 14, 15]. Moreover, in experimental models high salt also promotes pro-inflammatory phenotype of myeloid cells by enhancing cytokine production and polarization towards M1 phenotype, leading to an overall imbalance of immune homeostasis [14, 16, 17]. In accordance with these findings, a recent study demonstrated that increased sodium intake is associated with clinical disease exacerbation, augmented relapse risk, and increased magnetic resonance imaging (MRI) activity in MS patients [4].
However, larger clinical studies recently failed to show an association between salt intake and higher MS disease risk, progression, or activity [18, 19], thus the possible deleterious effect of HSD in MS is still under discussion.

Synucleinopathies such as Parkinson’s disease (PD) and multiple system atrophy (MSA) constitute neurodegenerative disorders characterized by autonomic failure, motor impairment and the abnormal accumulation of α-synuclein (α-syn) in the cytoplasm of either neurons (Lewy bodies, characteristics of PD) or in oligodendroglial cytoplasmic inclusions (GCIs, characteristics of MSA) [20–23]. The accumulation of α-syn in MSA brains is associated with microglial activation and neuro-inflammation [24–26], demyelination [27, 28], and neurodegeneration [29]. MSA is subdivided into two motor subtypes depending on the main brain areas affected by the pathology, the parkinsonian variant (MSA-P) characterized by striatonigral degeneration (SND) and the cerebellar variant (MSA-C) characterized by olivopontocerebellar atrophy (OPCA), but autonomic failure is present in both variants [30–32]. At present, there are no disease-modifying therapies to stop disease progression and only mitigation of some symptoms is feasible [33]. In this regard, increased fluid and salt intake is often recommended by physicians to alleviate neurogenic orthostatic hypotension [34].

The association of HSD with pro-inflammatory disorders together with the experimental evidence showing its deleterious effects in different in vitro and in vivo models questions the use of HSD in MSA and PD patients. The fact that neuroinflammation and the immune system, especially microglial cells, play an important role in MSA and PD pathogenesis [24–26, 35–37] and the recent evidences of a possible involvement of Th17 cells in PD [38–43] support these concerns. In order to evaluate the pathological consequences of HSD in α-synucleinopathies we have analyzed its effects in the PLP-haSyn transgenic mice model of MSA. Here, we show that high dietary intake of salt does not accelerate disease progression nor increase neuroinflammation, microglial activation, or neurodegeneration in MSA mice, suggesting that HSD may not have a pro-inflammatory effect in this particular α-synucleinopathy.

**Material and methods**

### Animals and treatments

Clinical and pathological features of MSA are recapitulated in the PLP-haSyn mouse model. These mice over-express human wildtype α-syn in oligodendrocytes under the myelin proteolipid protein (PLP) promoter [44] leading to the formation of GCI-like structures, autonomic failure, progressive SND, and motor impairment [44–54]. SND in the PLP-haSyn mice is characterized by a reduction in the number of dopaminergic neurons in the substantia nigra pars compacta (SNc) [55] followed by a reduction of the density of dopaminergic terminals and medium spiny neurons (MSNs) in the striatum linked to significant motor decline [51]. Similar to the human pathology, PLP-haSyn mice develop progressive microglial activation initially triggered by α-syn pathology [51, 53]. Our group has also previously shown that stressors relevant to human MSA, e.g., mitochondrial dysfunction [52] or proteolysis disruption [56], can aggravate the pathology in PLP-haSyn mice towards full-blown MSA with spreading of GCI, SND, OPCA, and strong microglial activation. In summary, the PLP-haSyn mouse model provides an important and relevant pre-clinical tool to study disease mechanisms of MSA progression downstream of the accumulation of α-syn in oligodendrocytes.

PLP-haSyn and C57BL/6 N wildtype animals were kept under temperature-controlled pathogen-free conditions on a light/dark 12 h cycle. Nine-month-old PLP-haSyn and wildtype animals were both randomized in 2 groups, one fed with normal food pellets (0.19% sodium; SSNIFF Spezialdiäten GmbH) and tap water, another fed with HSD (4% NaCl; SSNIFF Spezialdiäten GmbH) and tap water containing 1% NaCl as previously described [2, 6, 7]. After 3 months of treatment, the animals were sacrificed and brains were collected. Bodyweight of all animals was measured weekly throughout the treatment period (Additional file 1: Figure S1). Although PLP-haSyn mice presented lower body weight compared to healthy control animals, no differences due to diet were observed within the 2 animal groups (Additional file 2: Figure S1). All the experiments were performed according to the ethical guidelines of the EU (Directive 2010/63/EU for animal experiments) and the Austrian Federal Ministry of Science and Research (permission BMFWF-66.011/0018-WF/v/3b/2015). All analyses were done by a researcher who was blinded to the treatment of the animals.

**Stride length analysis**

Stride length analysis was performed with DigiGait™ Imaging System (Mouse Specifics Inc.) as previously described [51, 56]. Briefly, mice were placed onto a transparent treadmill belt and gait of each mouse was recorded with a video camera placed below the belt. Stride length was analyzed with DigiGait Software 9.0 (Mouse Specific, USA) and expressed in cm.

**Tissue processing and histology**

Animals were perfused intracardially with phosphate-buffered saline (PBS, pH 7.4, Sigma) under deep thiopental anesthesia and brains were extracted. Hemibrains were post-fixed overnight in 4% paraformaldehyde (pH
applied the optical fractionator workflow [51]. The striatum was measured and the positive area for IBA1 or CD68 was estimated using ImageJ (National Institutes of Health). Results are presented as percentage of IBA1 or CD68 area per section.

**Immunohistological analyses**
Free-floating sections were immunostained following standard protocols. Microglial activation was evaluated by immunofluorescence using antibodies against IBA1 (1:600, WAKO) and CD68 (1:200, R&D). In order to evaluate the level of SND, SNc sections were stained with anti-tyrosine hydroxylase (TH) antibody (1:1000, Millipore) and the number of dopaminergic (TH+) neurons was analyzed by stereological counting. Striatal sections were stained with anti-DARPP32 antibody (BD Biosciences; 1:2000) and the number of medium spiny neurons (MSNs; DARPP32+) was quantified. OPCA in the cerebellum was evaluated by DARPP32 immunostaining of Purkinje cells (DARPP32+). To analyze the number of GCIs, representative sections including SNc, cerebellar white matter (CBWM), and motor cortex (M2) were stained with anti-phosphorylated α-syn antibody (pS129; 1:1000, Abcam). For immunofluorescence, suitable secondary anti-IgG antibodies conjugated with Alexa 488 (Life Technologies) or Alexa 594 (Life Technologies) were applied and coverslipped with mounting medium Fluromount-G (Southern Biotech). For immunohistochemistry, sections were incubated with biotinylated secondary antibodies followed by Vectastain ABC reagent (Vector Laboratories) and 3,3′-diaminobenzidine (Sigma) to visualize the binding sites. Stained sections were mounted on slides, dehydrated, and coverslipped with Entellan (Merck).

**Image analyses**
Neuroanatomy was assessed using a Mouse Brain Atlas. For microglial activation assessment, images were acquired with a fluorescence microscope (Leica DMi4000) and the positive area for IBA1 or CD68 was estimated using ImageJ (National Institutes of Health). Results are presented as percentage of IBA1 or CD68 area per section total area. Stereological analysis was performed using the Nikon E-800 microscope equipped with Nikon digital camera DXM1200 and Stereoinvestigator software (Microbrightfield Europe e.K) as described previously [56]. The number of TH+ neurons in the SNc and DARPP-32+ neurons in the striatum was measured by applying the optical fractionator workflow [51]. The density of GCIs and Purkinje cells (DARPP32+) were assessed with meander scan and is expressed in GCI/mm² and DARPP32+ neurons/mm² respectively.

**RNA extraction and quantitative RT-qPCR**
For molecular analyses, hemibrains were quickly dissected in the forebrain, midbrain, cerebellum, and brainstem, frozen in liquid nitrogen and stored at −80 °C. RNA was extracted using TRIzol reagent (Life technologies) according to the manufacturer’s instructions. Tissue was homogenized with ULTRA-TURRAX T-8 basic tissue ruptor (IKA) in the presence of TRIzol. RNA samples (3 μg) were retrotranscribed to cDNA using High-Capacity cDNA Reverse Transcription Kit (Applied-Biosystems). Real time PCR was performed in a 7500 Real-Time PCR Systems (Applied-Biosystems) using TaqMan™ Universal PCR Master Mix (Applied-Biosystems). Gapdh mRNA levels were estimated to normalize for mRNA input amounts. TaqMan probe sequences are available upon request. mRNA levels were obtained using the 2−ΔΔCt method and expressed as fold-change relative to the wildtype normal diet control group [57].

**Cytokine/chemokine levels**
Fresh frozen forebrain, midbrain, cerebellum, and brainstem were homogenized in Triton-X (TX) extraction buffer (50 mM Tris-base pH 7.6, 150 mM NaCl, 1% Triton-X-100, 2 mM EDTA) containing protease and phosphatase inhibitors. The lysates were centrifuged (16, 000×g for 10 min at 4 °C) to remove debris and the supernatant was collected and stored at −80 °C. Protein concentrations were determined with BCA Protein Assay Kit (Sigma). ProcartaPlex® Multiplex Immunoassay system (eBioscience, Waltham, MA USA) was used to simultaneously measure the concentration of different cytokines and chemokines. The same protein amount was loaded for all samples. Duplicates were performed per each sample and mean values were calculated for subsequent statistical analysis. Data are presented as pg cytokine/chemokine per mg total protein.

**Dot blot analysis of soluble α-syn**
Lysates obtained previously were ultra-centrifuged (100, 000×g for 60 min at 4 °C) and the supernatant was collected and stored at −80 °C. Equal amounts of protein (5 μg) per sample were spotted onto nitrocellulose membranes (GE Healthcare) and air-dried for 30 min. Membranes were incubated overnight at 4 °C in blocking buffer (PBS, pH 7.6, 0.1% Tween 20, 5% non-fat dry milk) with primary antibody against human α-syn (4B12; 1:1000, Genetex). Signal detection was performed using HRP-conjugated secondary antibodies and WesternBright Quantum kit (Advanta). Images were acquired using the Fusion FX system for western blot and gel imaging and quantified with FUSION CAPT V16.09b software (Vilber Lourmat).
Statistical analyses
All statistical analyses were conducted using the software Graph-Pad Prism 7 (Graphpad Software). The mean ± S.E.M was used to present the results. Two-way analysis of variance (ANOVA) with post hoc Bonferroni test was used to compare the groups if not indicated otherwise. A p value < 0.05 was considered statistically significant.

Results
High-salt diet causes partial upregulation of genes linked to microglial and astroglial activation without changes at protein level in PLP-haSyn brains
To assess the effect of HSD on microglia we performed histological and molecular analyses for two different markers of microglial activation, IBA1 and CD68 [58, 59]. The increase of IBA1 and CD68 levels has been associated with α-syn accumulation and neurodegeneration in PD and MSA animal models [51, 53, 60–65]. In agreement with previous data [51], significant microglial activation was observed in PLP-haSyn mouse brains compared to healthy controls (Fig. 1). Gene expression analysis showed upregulation of Cd68mRNA in the forebrain, midbrain and cerebellum of PLP-haSyn mice (Fig. 1a). A significant upregulation of Cd68mRNA was also observed in the HSD PLP-haSyn group compared to PLP-haSyn mice fed with normal diet (Fig. 1a). However, immunohistological analysis only showed a significant increase of CD68 in PLP-haSyn mice compared to healthy control animals with no specific effect of diet (Fig. 1b, c). Higher levels of CD68 were observed by immunofluorescence in striatum, substantia nigra (SN), pontine nuclei (PN), and cerebellar white matter (CBWM) of PLP-haSyn animals compared to wildtypes with no effect of diet either in PLP-haSyn or healthy control mice, keeping both high-salt groups similar levels to their normal diet groups (Fig. 1b, c). Similar results were obtained with IBA1 (Fig. 1d–f). A significant upregulation of Iba1mRNA was observed in the midbrain and cerebellum of PLP-haSyn mice compared to wildtype animals (Fig. 1d). Immunohistological analyses showed a significant increase of IBA1 in the SN, PN, and cerebellum of transgenic vs control mice (Fig. 1e, f). No effects of the diet were observed either in PLP-haSyn or in healthy control animals discarding a specific effect of diet on microglial activation (Fig. 1e, f).

In order to assess the role of astroglia in the inflammatory response observed in PLP-haSyn mice, we analyzed in the brain subregions the expression levels of Gfap (glial fibrillary acidic protein), a marker of astrogliosis. Significant upregulation of Gfap mRNA was only observed in the cerebellum of PLP-haSyn with no effect of diet, discarding a general involvement of astroglia in neuroinflammation (Additional file 2: Figure S2).

High-salt diet does not interfere with the neuroinflammatory signaling in the PLP-haSyn brain
To further characterize the subregion-specific effect of HSD on neuroinflammation in PLP-α-syn mice, we evaluated separately the levels of 36 cytokines and chemokines in forebrain, midbrain, cerebellum, and brainstem by using a multi-analyte detection system (Fig. 2a, b). Heatmap portraying the overall changes of cytokines/chemokines in PLP-haSyn and control mice showed different profiles between genotypes but no effect of diet (Fig. 2a). The analysis revealed a significant increase of CCL3, CCL4, and CCL5 chemokines in PLP-haSyn mouse brains compared to wildtype animals but no effect of salt (Fig. 2a-b and Additional file 3: Figure S3). The brain concentration of the remaining analytes showed no significant effect of genotype or diet (Additional file 4: Tables S1–S4).

We also evaluated changes in the adaptive immune system by analyzing the gene expression levels of two markers of T lymphocytes, Cd4, and Cd8. RT-qPCR analysis showed no changes between animal groups (Fig. 2c and Additional file 3: Figure S3), excluding an effect of the synucleinopathy or diet on T cell recruitment and discarding the involvement of the adaptive immune system in neuroinflammation in PLP-haSyn mice (Fig. 2c and Additional file 3: Figure S3).

High-salt diet causes no deterioration of motor impairment, neurodegeneration, and myelin dysfunction in PLP-haSyn mice
In order to evaluate the effect of diet on the gait impairment, we performed Digigait behavioral test. PLP-haSyn mice showed a significant reduction of stride length compared to healthy control mice with no effect of diet on motor impairment (Fig. 3a). To assess the consequences of HSD on SND, the number of dopaminergic (TH+) neurons in the SNc and the number of MSNs (DARPP-32+) in the striatum were quantified in control and PLP-haSyn mice. As previously described [51], stereological counting showed significant loss of TH+ and DARPP-32+ neurons in SNc and striatum respectively of PLP-haSyn mice compared to wildtype animals (Fig. 3b–d). We did not detect any effect of diet neither in control nor in PLP-haSyn mice (Fig. 3b–d). OPCA was evaluated by the stereological counting of Purkinje cells (DARPP32+) in the cerebellar cortex of PLP-haSyn and control animals (Fig. 3e). No changes in the number of Purkinje neurons in the cerebellar cortex were observed between animal groups (Fig. 3e), discarding an expansion of the pathology after high-salt exposure similar to the ones observed previously after oxidative stress insult or proteasome inhibition [52, 56]. We also performed a subregion-specific evaluation of the effect of diet on myelin (Fig. 3f and Additional file 3: Figure S3).
Fig. 1 (See legend on next page.)
Gene expression analysis showed significant downregulation of *Mbp* mRNA (myelin basic protein) in PLP-haSyn mice compared to healthy controls in most brain subregions (Fig. 3f and Additional file 3: Figure S3). However, we did not observe diet-associated differences neither in control nor in PLP-haSyn animals, thus excluding a possible role of HSD in motor impairment, neurodegeneration, or myelination dysfunction (Fig. 3 and Additional file 3: Figure S3).

**High-salt diet does not affect α-syn pathology in PLP-haSyn mice**

To fully evaluate the effect of HSD in the PLP-haSyn mouse model, we assessed α-syn accumulation by histological and molecular analyses. In order to do that, representative brain sections of SNc, CBWM, and motor cortex (M2) were stained with anti-phosphorylated (p-S129) α-syn antibody and the density of GCIs was quantified (Fig. 4a, b). HSD showed no effect on GCI number in any of the regions analyzed (Fig. 4a, b). We also performed subregion-specific dot blot analysis of soluble α-syn (Fig. 4c, d). Significant higher levels of soluble α-syn were found in all brain subregions of PLP-haSyn mice compared to wildtype animals, but no effect of diet was observed (Fig. 4c, d). Therefore, an effect of diet on α-syn accumulation was discarded.

**Discussion**

Recently, several publications have associated HSD with activation of the immune system and neuroinflammation in experimental models of different neurological disorders, including MS [2–7, 11, 14, 16, 17, 66]. Despite the possible deleterious effect of salt on neuroinflammation, a high dietary intake of salt constitutes one of the most recommended non-pharmacological approaches to treat autonomic symptoms in MSA and PD patients [34]. Since microglial activation and neuroinflammation constitute two of the main pathological features of MSA and PD [24–26, 35–37], the use of HSD could aggravate CNS pathology by enhancing microglial activation, neuroinflammation, and the infiltration of peripheral immune cells.

In order to evaluate the effect of HSD on CNS pathology in α-synucleinopathies, PLP-haSyn and wildtype animals were both fed with food pellets containing 0.19% (control diet) or 4% NaCl (high-salt diet). HSD consisting 4% NaCl constitutes an increase of about 8–19 times depending on the salt content in normal diet food pellets, which usually range between 0.19 and 0.4% depending on the study. For the human general population, the level of sodium intake recommended in major dietary guidelines ranges from 1200 to 2300 mg per day [67–70]. However, in MSA and PD, physicians often prescribe increased salt intake to around 10 g of salt per day [71–73], being 4–7 times higher than dietary recommendation for the general population. Thus, the experimental approach used in the present study is comparable to the spectrum of human salt consumption and may reflect changes due to HSD similar, or even stronger, than those expected in MSA and PD patients treated with salt. The deleterious effect of HSD in the CNS has also been described in rodents after exposure to 8% NaCl food pellets [11, 74]. However, this may not reflect physiological and clinically relevant conditions since it represents an increase of dietary salt intake of about 16–40 times compared to the normal diet.

Here, we demonstrate that HSD does not affect the activation of microglial cells in PLP-haSyn mice. Previous results from our group have shown a progressive increase in microglial activation with disease progression in this animal model [51] that can also be augmented in the presence of second deleterious stimuli such as mitochondrial dysfunction or proteasome impairment [52, 56]. In contrast, HSD did not increase microglial activation in the present study according to different molecular and histological analyses. We have also previously shown that the total number of microglial/macrophage cells (IBA1+) does not change in the CNS of MSA mice with disease progression and instead only an increase in their activation state is observed [51]. Therefore, the infiltration of peripheral macrophages in PLP-haSyn mouse brains appears to be unlikely. Our results differ from experimental studies of inflammatory disorders associated with CNS infiltration of peripheral and monocyte-derived macrophages, where HSD increases activation and polarization towards an M1 phenotype [14, 16, 17] (Fig. 5). The difference between those studies and ours may reflect distinct cell-specific responses of
Fig. 2 High-salt diet does not affect neuroinflammation in MSA mice. 

**A** Heat map comparing the log2 fold change in cytokine and chemokine expression in different brain regions of MSA mice fed with/without high-salt diet and control mice fed with high-salt, as referred to control mice fed with a normal diet. **B** Protein levels of CCL3, CCL4 and CCL5 chemokines in the midbrain. Protein levels are expressed in pg of protein of interest per mg of total proteins. **C** Relative gene expression of T-cell markers Cd4 and Cd8 in the midbrain. The data is expressed in fold change relative to WT mice fed with a normal diet. Error bars indicate SEM. Two-way ANOVA: *p < 0.05, **p < 0.01, ****p < 0.0001 (Bonferroni’s test).
peripheral macrophages and microglial cells to HSD due to their different developmental origin and activation patterns [75–78]. However, further analyses are required to fully understand these differences.

We also show that HSD does not interfere with neuroinflammation, astroglial activation, or T cell CNS infiltration in PLP-haSyn mice. The absence of changes in different markers of T lymphocytes (CD4 and CD8) and their associated proinflammatory cytokines and chemokines (i.e., IFN-γ, IL-17, IL-12, IL-23) [13, 79–83] in the brain of MSA mice compared to wildtype animals suggest that these cells are not critical in the
neuroinflammatory process observed in PLP-αSyn mice. Moreover, human studies have shown no clear evidence of T cell involvement in MSA so far. The absence of a higher activation of the immune system in PLP-αSyn mice could explain the differences with HSD studies in EAE models of MS where activation and infiltration of T cells and peripheral macrophages in the CNS accelerate disease onset, augment its severity, and enhance brain pathology [6–10, 12, 14, 15] (Fig. 5). However, the results obtained from our study cannot be...
extrapolated to PD, where an association between T cells and neurodegeneration has been recently suggested [38–43]. Further studies including pre-clinical models of PD are needed to clarify the effect of HSD on underlying neuropathology.

HSD did not affect neurodegeneration or demyelination in MSA mice. Although PLP-haSyn animals develop SND and myelin dysfunction characterized respectively by a significant loss of dopaminergic neurons in the SNC and MSNs in the striatum and a downregulation of the Mbp gene in several brain subregions, no changes were observed after HSD exposure in these mice. These findings again differ from the studies in EAE models of MS where HSD has led to enhanced demyelination [14, 15]. In agreement with our data, a large clinical study has recently revealed that salt intake does not influence MS disease course or activity thus indicating that EAE models, which are induced by active immunization with myelin components or by passive transfer of autoreactive T cells, do not necessarily reflect the human disease [18, 84]. In contrast to the MSA model used in our study, where neuroinflammation is a secondary event induced by the aggregation of α-syn in oligodendrocytes [51, 53], neuroinflammation is a primary event induced by a peripheral immune response in the EAE models used for the studies on salt intake [9, 12, 13, 84]. Thus, the differences in the effects of diet on the neuropathology of MSA and MS animal models could also be explained by the absence of neuroinflammatory changes induced by HSD in PLP-haSyn mice (Fig. 5).

Fig. 5 Pathophysiological features of MSA and EAE models and potential pathogenic effect of a high-salt diet. a Schematic overview of the central nervous system in healthy conditions. In MSA, α-syn accumulates in the cytoplasm of oligodendrocytes inducing oligodendroglial dysfunction. Soluble α-syn oligomeric species spread through the brain parenchyma and trigger microglial activation and neuroinflammation. All these events lead to demyelination and neurodegeneration. High-salt diet exposure has no effect on the CNS of PLP-haSyn mice possibly due to the absence of peripheral immune cell involvement in MSA brain pathology. c EAE mice model mimics many features of MS, such as blood-brain barrier (BBB) disruption, demyelinating lesions associated with infiltrating T cells, macrophages, and B cells, microglial activation, neuroinflammation, and neurodegeneration. In EAE mice, high-salt diet increases activation and infiltration of T cells and peripheral macrophages in the CNS accelerating disease onset, augmenting its severity and enhancing blood-brain barrier disruption and brain pathology.
Previous results from our group have shown that a combination of synucleinopathy with second hit stimuli such as oxidative stress or proteasome inhibition can aggravate the pathology in PLP-hαSyn mice towards full-blown MSA with strong microglial activation and spreading of SND, OPCa, and GClis [52, 56]. However, PLP-hαSyn mice showed no changes in α-syn accumulation after HSD exposure by neither molecular nor histological analyses, therefore excluding an effect of diet on any of the synucleinopathy features.

In contrast to our observations, two recent studies by Faraco et al. have shown that HSD induces cognitive impairment in wildtype animals [11, 74]. Faraco et al. observed significant deleterious effects in wildtype mice after 12 weeks of HSD with 4% NaCl food pellets, a similar protocol to the one used in our study. However, we did not find differences between wildtype animals fed with normal or HSD. These differences may be explained by the use of different mouse substrains. The PLP-hαSyn and control animals used in our study were C57BL/6 N. Unfortunately, Faraco et al. do not mention which specific C57BL/6 substrain was used in their study. It has been shown that C57BL/6 substrains present behavioral [85] and genetic differences—including immune function—[86]. Moreover, other groups have shown that HSD has either no effect or even ameliorates symptoms in animal models of other inflammatory disorders [87, 88]. Thus, the differences between our data and previous HSD studies, and in particular data in EAE mice, may be explained by the use of different mouse strains or by the different experimental approaches used to boost the inflammatory process, as previously discussed.

Despite the publications supporting the deleterious effect of HSD in experimental models of MS, two large clinical studies failed to show an association between salt intake and higher MS disease risk, progression, or activity [18, 19]. Moreover, although sodium intake differs between East Asian, American, and European population [89], MSA cohort study groups from Japan, Europe, and the USA show a similar median survival [90–92], supporting the current findings and suggesting that salt consumption differences may not affect disease progression in MSA.

Several limitations of the current study need to be acknowledged. Despite not having observed an effect of diet in the CNS of MSA mice, we cannot exclude an effect in peripheral organs. Moreover, in the present study, we have not evaluated the effect of HSD on cardiovascular regulation or pathology. Among the different autonomic cardiovascular problems present in MSA patients, the presence of orthostatic hypotension (OH) constitutes one of the major criteria for diagnosis [93]. Data from our group show cardiovascular defects in PLP-hαSyn mice [50], but it is not possible to address the issue of OH in a mouse model. In this regard, we cannot exclude a role of high sodium intake on neuropathology linked to OH in MSA patients. However, the analysis of the effect of diet in both the peripheral immune system and the different cardiovascular features of PLP-hαSyn mice is beyond the scope of the present study, where the main objective was to study the effect of HSD in the neuroinflammatory process underlying MSA pathology in the CNS.

Conclusions
Here, we demonstrate that HSD does not interfere with microglial activation, neuroinflammation, motor function, neurodegeneration, and α-syn accumulation in the PLP-hαSyn mouse model of MSA, making deleterious effects of HSD on brain pathology and its progression unlikely. Our findings contrast with experimental data obtained in EAE models of MS and do not support a pro-neuroinflammatory effect of the current clinical practice of a high-salt diet for the treatment of autonomic failure in MSA.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12974-020-1714-y.

Additional file 1: Figure S1. Animal body weight. Body weight of healthy control mice fed with normal diet (WT; white circles) or HSD (WT + HSD; gray circles) and PLP-hαSyn mice fed with normal diet (TG; black squares) or HSD (TG + HSD; red squares). Body weight was measured weekly throughout the treatment period.

Additional file 2: Figure S2. High-salt diet does not affect astroglisis in MSA mice. Gene expression (mRNA) levels in forebrain, midbrain, cerebellum and brainstem of the astrocyte marker Gfap. mRNA levels are expressed in fold change relative to WT mice fed with normal diet. White bars: WT mice; Gray bars: WT mice fed with HSD (TG + HSD); Black bars: TG mice; Red bars: TG mice fed with HSD (TG + HSD). Error bars indicate SEM. Two-way ANOVA: *** p < 0.001, **** p < 0.0001 (Bonferroni’s test).

Additional file 3: Figure S3. Protein levels and gene expression (mRNA) levels in forebrain, cerebellum and brainstem of the main proteins and genes analyzed on the study. Protein levels are expressed in pg of protein of interest per mg of total proteins. mRNA levels are expressed in fold change relative to WT mice fed with normal diet. White bars: WT mice; Gray bars: WT mice fed with HSD (TG + HSD); Black bars: TG mice; Red bars: TG mice fed with HSD (TG + HSD). Error bars indicate SEM. Two-way ANOVA: * p < 0.05, ** p < 0.01, *** p < 0.001 (Bonferroni’s test).

Additional file 4: Tables S1. Cytokine and chemokine protein levels in forebrain. The table represent the concentrations (pg/mg total protein) of the different cytokines and chemokines measured in forebrain of control and MSA mice fed with normal or high salt diet. Data are presented as mean ± SD. p-values where obtained by two-way ANOVA with Bonferroni’s post hoc test. Table S2. Cytokine and chemokine protein levels in midbrain. The table represent the concentrations (pg/mg total protein) of the different cytokines and chemokines measured in midbrain of control and MSA mice fed with normal or high salt diet. Data are presented as mean ± SD. p-values where obtained by two-way ANOVA with Bonferroni’s post hoc test. Table S3. Cytokine and chemokine protein levels in cerebellum. The table represent the concentrations (pg/mg total protein) of the different cytokines and chemokines measured in cerebellum of control and MSA mice fed with normal or high salt diet. Data are presented as
mean ± SD. p-values where obtained by two-way ANOVA with Bonferroni’s post hoc test. Tables S4: Cytokine and chemokine protein levels in brainstem. The table represent the concentrations (pg/mg total protein) of the different cytokines and chemokines measured in forebrain of control and MSA mice fed with normal or high salt diet. Data are presented as mean ± SD. p-values where obtained by two-way ANOVA with Bonferroni’s post hoc test.

Abbreviations
CBWM: Cerebellar white matter; CNS: Central nervous system; EAE: Experimental autoimmune encephalomyelitis; GCIs: Glial cytoplasmic inclusions; HSD: High-salt diet; MS: Multiple sclerosis; MSA: Multiple system atrophy; MSNs: Medium spiny neurons; nOH: Neurogenic orthostatic hypotension; OPCA: Olivopontocerebellar atrophy; PD: Parkinson’s disease; PN: Pontine nuclei; SN: Substantia nigra; SNc: Substantia nigra pars compacta; SND: Striatonigral degeneration; TH: Tyrosine hydroxylase; a-syn: Alpha-synuclein

Acknowledgements
Not applicable.

Authors’ contributions
APK contributed to the acquisition, analysis, and interpretation of data, helped to draft and revise the manuscript, and gave final approval of the submission. MR contributed to the acquisition of data, revised the manuscript, and gave final approval of the submission. GW and NS contributed to the conception and design, helped in the interpretation of data, revised the manuscript, and gave final approval of the submission. All authors read and approved the final manuscript.

Funding
The study was supported by grants of the Austrian Science Fund (FWF) F4414, W1206-08 and a grant of the European Community work Programme (FP7/2007–2013) under agreement n 602646 (Multisyn).

Availability of data and materials
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
All the experiments were performed according to the ethical guidelines of the EU (Directive 2010/63/EU for animal experiments) and the Austrian Federal Ministry of Science and Research (permission BMFW-66011/60018-WFv/36/2015).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Neurology, Division of Neurobiology, Medical University of Innsbruck, Innsbruck 66, 6020 Innsbruck, Austria. 2Department of Neurology, Neuroimmunology Research Group, Medical University of Innsbruck, Innsbruck 66, 6020 Innsbruck, Austria.

Received: 3 October 2019 Accepted: 13 January 2020

References
1. Sundstrom B, Johansson I, Rantapaa-Dahlqvist S. Interaction between dietary sodium and smoking increases the risk for rheumatoid arthritis: results from a nested case-control study. Rheumatology (Oxford). 2015;54(3): 487–93.
2. Gilman TL, Mitchell NC, Daws LC, Toney GM. Neuroinflammation contributes to high salt intake-augmented neuronal activation and active coping responses to acute stress. Int J Neurspsychopharmacol. 2019;22(2):137–42.
3. Janakiraman M, Krishnamoorthy G. Emerging role of diet and microbiota interactions in Neuroinflammation. Front Immunol. 2018;9:2067.
4. Farez MF, Fiol MP, Gaitan MI, Quintana FJ, Correa J. Sodium intake is associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):26–31.
5. Huckle S, Wiendl H, Klotz L. Implications of dietary salt intake for multiple sclerosis pathogenesis. Mult Scler. 2016;22(2):133–9.
6. Kleinewefeld M, Manzel A, Titze J, Kvakun H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmunity by the induction of pathogenic TH17 cells. Nature. 2013;496(7446):518–22.
7. Wu C, Yosef N, Thalhammer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase 3GK1. Nature. 2013;496(7446):513–7.
8. Codarri L, Győrizs G, Gosevski V, Hessle J, Fontana A, Magennat L, et al. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011;12(6):560–7.
9. Kebrì H, Kreymborg K, Ilgeran I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13(10):1175–5.
10. Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10(5):514–23.
11. Faraco G, Beja D, Garcia-Bonilla L, Wang G, Racchumi G, Chang H, et al. Dietary sodium salt primes neurovascular and cognitive dysfunction through a gut-initiated TH17 response. Nat Neurosci. 2018;21(2):240–9.
12. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain J Neurosci. 2006;129(Pt 8):1953–71.
13. Segal BM. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical TH1-mediated autoimmune disease. Curr Allergy Asthma Rep. 2003;3(1):86–93.
14. Huckle S, Eschborn M, Liebmann M, Hercold M, Freise N, Engbers A, et al. Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity. J Autoimmun. 2016;67:90–101.
15. Krementsov DN, Case LK, Hickey WF, Teuscher C. Exacerbation of autoimmune neuroinflammation by dietary sodium is genetically controlled and sex specific. FASEB J. 2015;29(8):3446–57.
16. Zhang WC, Zheng XJ, Du LJ, Liu SY, Shen ZX, Shi C, et al. High salt primes a specific activation state of macrophages, M (Na). Cell Res. 2015;25(8):893–910.
17. Binger KJ, Gebhardt M, Heinig M, Rintisch C, Schroeder A, Neuhofer W, et al. High salt reduces the activation of IL-4- and IL-13-stimulated macrophages. J Immunol. 2009;182(5):2875–84.
18. Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalban X, Edan G, et al. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Ann Neurol. 2017;82(1):20–9.
19. Cortese M, Yuan C, Chitnis T, Ascherio A, Munger KL. No association between dietary sodium intake and the risk of multiple sclerosis. Neurology. 2017;89(13):1322–9.
20. Fanclulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372(3):249–63.
21. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakos R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40.
22. Trojanowski JQ, Lee VM. Parkinson’s disease and related alpha-synucleinopathies are brain amyloidoses. Ann N Y Acad Sci. 2003;991:107–10.
23. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neuro. 1998;44(3):415–22.
24. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, et al. [11C]PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003;61(5):685–9.
25. Ishizawa K, Komori T, Sasaki S, Araki N, Mizutani T, Hiseo T. Microglial activation parallels systemic degeneration in multiple system atrophy. J Neuropathol Exp Neurol. 2004;63(1):43–52.
26. Vieira BD, Radford RA, Chung RS, Guillemín GJ, Pountney DL. Neuroinflammation in multiple system atrophy: response to and cause of alpha-Synuclein aggregation. Front Cell Neurosci. 2015;9:437.
27. Don AS, Hsiao JH, Beaeal JM, Coutts TA, Halliday GM, Kim WS. Altered lipid levels provide evidence for myelin dysfunction in multiple system atrophy. Acta Neuropathol Commun. 2014;2:150.

28. Ishizawa K, Komori T, Ari N, Mizutani T, Hirose T. Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: a quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system). Neuropathology. 2008;28(3):249–57.

29. Stefanova N, Wenning GK. Review: multiple system atrophy: emerging targets for interventional therapies. Neuropathol Appl Neurol Biol. 2016;42(1):20–32.

30. Ahmed Z, Ali YT, Sailer A, Lees AJ, Houlden H, Revesz T, et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurol Biol. 2012;38(1):4–24.

31. Ozawa T, Pavlou D, Quinn NP, Josephs KA, Sangha H, Kliford L, et al. The spectrum of pathological involvement of the striatongral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain. 2004;127(Pt 12):2657–71.

32. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology. 2007;27(5):484–93.

33. Eschbock S, Krismer F, Wenning GK. Interventional trials in atypical parkinsonism. Parkinsonism Relat Disord. 2016;22(Suppl 1):S82–92.

34. Metzler M, Duer S, Granata R, Krismer F, Robertson D, Wenning GK. Neonatal orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol. 2013;260(9):2212–19.

35. Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182–92.

36. Stevens CH, Voevodin EV, Morel-Kopp MC, Orr C, Russell T, Ranola M, et al. Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol. 2012;252(1–2):195–9.

37. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1998;50(8):285–91.

38. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. Synapse. 2013;67(3):94–103.

39. Kuzdas D, Stemberger S, Gaburro S, Stefanova N, Singewald N, Wenning GK. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. Exp Neurol. 2013;247(3):1–6.

40. Refolo V, Bez F, Polissidis A, Kuzdas-Wood D, Sturm E, Kamaratos M, et al. Progressive striatongrial degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. Acta Neuropathol Commun. 2018;6(1):12.

41. Stefanova N, Reindl M, Neumann M, Haas C, Poewe W, Kahle P, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol. 2005;166(3):869–76.

42. Stefanova N, Reindl M, Neumann M, Kahle P, Poewe W, Wenning GK. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord. 2007;22(15):2196–203.

43. Stemberger S, Poewe W, Wenning GK, Stefanova N. Overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp Neurol. 2010;224(2):659–64.

44. Bassil F, Fernagut PO, Bezard E, Pruvo A, Leste-Lasserre T, Hoang QQ, et al. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A. 2016;113(34):9593–8.

45. Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter. Implications for multiple system atrophy. Acta Neuropathol. 2012;124(1):51–65.

46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–8.

47. Ito D, Imai Y, Ohara K, Nakajima K, Fukushima Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res. 1998;57(1):11–9.

48. Zottova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer's disease and after active amyloid-beta42 immunization. Brain. 2013;136(Pt 9):2677–96.

49. Austin SA, Floden AM, Murphy EJ, Combs KC. Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci. 2006;26(41):10558–63.

50. Doorn KJ, Moores T, Drukker B, van de Berg W, Lucassen PJ, van Dam AM. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients. Acta Neuropathol Commun. 2014;2:90.

51. Fellner L, Ishichik R, Schanda K, Reindl M, Klimaschewski L, Poewe W, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013;61(4):394–40.

52. Sanchez-Guajardo V, Barnum CJ, Tansey MG, Romero-Ramos M. Neuroimmunological processes in Parkinson's disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro. 2013;5(2):113–39.

53. Theodore S, Cao S, McLean PJ, Standaard DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neurophysiol. Exp Neurol. 2008;67(12):1149–58.

54. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19(6):533–42.

55. Zhang T, Fang S, Wan C, Kong Q, Wang G, Wang S, et al. Evasion salt exacerbates blood-brain barrier disruption via a p38 MAPK/SGLT1-dependent pathway in permanent cerebral ischemia. Scit Rep. 2015;5:16548.

56. Guideline: Sodium Intake for Adults and Children. WHO Guidelines Approved by the Guidelines Review Committee. Geneva. 2012.

57. Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126(24):2880–9.

58. Application of lower sodium intake recommendations to adults—United States, 1999–2006. MMWR Morb Mortal Wkly Rep. 2009;58(11):281–3.

59. Dietary Guidelines for Americans, 2010. Agriculture USD, Services USDHarH. Washington. 2011.
71. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as a, B, C. Cleve Clin J Med. 2010;77(5):298–306.

72. El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart. 1996;75(2):134–8.

73. Gilhus NE, Barnes MP, Brainin M, Lahmann H, Cortelli P, Hitz M, Mathias CJ, Stohl W, Tassinari M. Orthostatic Hypotension. Eur Handb Neurol Manag. 2010.

74. Faraco G, Hochrainer K, Segarra SG, Schaeffer S, Santisteban WM, Menon A, et al. Dietary salt promotes cognitive impairment through tau phosphorylation. Nature. 2019;574(7780):686–90.

75. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841–5.

76. London A, Cohen M, Schwartz M. Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci. 2013;7:34.

77. Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2018;18(6):225–42.

78. Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsh AM, Cialic R, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med. 2014;211(8):1533–49.

79. Kroenke MA, Segal BM. IL-23 modulated myelin-specific T cells induce EAE via an IFNgamma driven, IL-17 independent pathway. Brain Behav Immun. 2011;25(5):932–7.

80. Liu J, Lin F, Strainic MG, An F, Miller RH, Altuntas CZ, et al. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production. J Immunol. 2008;180(1):5882–9.

81. Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, McFarland HF. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Acta Neuropathol. 1993;15(2):137–43.

82. Bryant CD, Zhang NN, Sokoloff G, Fanselow MS, Ennes HS, Palmer AA, et al. Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J Neurogenet. 2008;22(4):315–31.

83. Simon MM, Greenaway S, White JK, Ennes H, Gailus-Durner V, Wells S, et al. A comparative phenotypic and genomic analysis of C57BL/6J and C57BL/6N mouse strains. Genome Biol. 2013;14(7):R82.

84. Kocenke MA, Segal BM. IL-23 modulated myelin-specific T cells induce EAE via an IFNgamma driven, IL-17 independent pathway. Brain Behav Immun. 2011;25(5):932–7.

85. Bryant CD, Zhang NN, Sokoloff G, Fanselow MS, Ennes HS, Palmer AA, et al. Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J Neurogenet. 2008;22(4):315–31.

86. Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, McFarland HF. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Acta Neuropathol. 1993;15(2):137–43.

87. Kocenke MA, Segal BM. IL-23 modulated myelin-specific T cells induce EAE via an IFNgamma driven, IL-17 independent pathway. Brain Behav Immun. 2011;25(5):932–7.

88. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol. 2009;10(3):314–24.

89. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, et al. Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open. 2013;3(12):e003733.

90. Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125(Pt 5):1070–83.

91. Wenning GK, Geser F, Krismer F, Seppi K, Duers S, Boechs S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12(3):264–74.

92. Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14(7):710–9.

93. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.